Rallybio Corporation (RLYB) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
234 CHURCH STREET NEW HAVEN, CT 06510 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments, including: | 109,900 | 169,000 | 175,334 | |||
| Cash and cash equivalents | 24,494 | 56,958 | 175,334 | |||
| Short-term investments | 85,435 | 112,036 | ||||
| Other undisclosed cash, cash equivalents, and short-term investments | (29) | 6 | ||||
| Prepaid expense | 739 | 1,548 | ||||
| Deferred costs | 100 | |||||
| Other current assets | 2,054 | 1,050 | ||||
| Other undisclosed current assets | 2,096 | 7,798 | 5,535 | |||
| Total current assets: | 114,789 | 179,496 | 180,869 | |||
| Noncurrent Assets | ||||||
| Operating lease, right-of-use asset | 346 | 524 | ||||
| Property, plant and equipment | 246 | 385 | 511 | |||
| Long-term investments and receivables | 239 | 30 | 805 | |||
| Long-term investments | 239 | 30 | 805 | |||
| Total noncurrent assets: | 831 | 939 | 1,316 | |||
| TOTAL ASSETS: | 115,620 | 180,435 | 182,185 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities | 9,044 | 10,563 | 6,551 | |||
| Accounts payable | 976 | 1,114 | 603 | |||
| Accrued liabilities | 8,068 | 9,449 | 5,948 | |||
| Deferred revenue | ||||||
| Other undisclosed current liabilities | 219 | 181 | ||||
| Total current liabilities: | 9,263 | 10,744 | 6,551 | |||
| Noncurrent Liabilities | ||||||
| Liabilities, other than long-term debt | 173 | 374 | 32 | |||
| Accounts payable and accrued liabilities | 32 | |||||
| Deferred revenue | ||||||
| Operating lease, liability | 173 | 374 | ||||
| Total noncurrent liabilities: | 173 | 374 | 32 | |||
| Total liabilities: | 9,436 | 11,118 | 6,583 | |||
| Equity | ||||||
| Equity, attributable to parent | 106,184 | 169,317 | 175,602 | |||
| Common stock | 4 | 4 | 3 | |||
| Additional paid in capital | 341,410 | 330,208 | 269,626 | |||
| Accumulated other comprehensive income (loss) | 15 | (214) | ||||
| Accumulated deficit | (235,245) | (160,681) | (94,027) | |||
| Total equity: | 106,184 | 169,317 | 175,602 | |||
| TOTAL LIABILITIES AND EQUITY: | 115,620 | 180,435 | 182,185 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Revenues (Other undisclosed Revenues) | |||||
| Gross profit: | |||||
| Operating expenses | (78,932) | (67,884) | (45,648) | ||
| Operating loss: | (78,932) | (67,884) | (45,648) | ||
| Nonoperating income | 6,409 | 2,305 | 140 | ||
| Other nonoperating income | 262 | 342 | 96 | ||
| Interest and debt expense | (10) | ||||
| Loss from continuing operations before equity method investments, income taxes: | (72,523) | (65,579) | (45,518) | ||
| Loss from equity method investments | (2,041) | ||||
| Other undisclosed income from continuing operations before income taxes | 10 | ||||
| Loss from continuing operations: | (74,564) | (65,579) | (45,508) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (45,508) | |
| Other undisclosed net loss | (1,505) | ||||
| Net loss: | (74,564) | (65,579) | (47,013) | ||
| Other undisclosed net loss attributable to parent | (1,075) | ||||
| Net loss available to common stockholders, diluted: | (74,564) | (66,654) | (47,013) | ||
Comprehensive Income ($ in thousands)
| 6/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Net loss: | (74,564) | (65,579) | (47,013) | ||
| Other comprehensive income (loss) | 229 | (214) | |||
| Comprehensive loss: | (74,335) | (65,793) | (47,013) | ||
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (1,075) | ||||
| Comprehensive loss, net of tax, attributable to parent: | (74,335) | (66,868) | (47,013) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.